The U.S. Food and Drug Administration has approved a new drug that, for the first time, has been shown to reduce the risk of death in patients with a severe form of Niemann-Pick disease type C (NPC), a rare and progressive genetic disorder. The treatment, called Lembaz (adrabetadex) injection, is approved for adult and pediatric patients weighing at least 7 kilograms (about 15 pounds) whose neurological symptoms began before age 6 — a condition known as infantile-onset NPC, according to an FDA press release issued November 17, 2026.
NPC is a rare, inherited lysosomal storage disorder that affects an estimated 1 in 150,000 people. In people with NPC, cells in the body are unable to correctly break down cholesterol and other fats. These materials build up over time, especially in the brain, leading to a worsening of neurological function, such as impaired movement, coordination, and swallowing. Those who develop neurological signs before turning 6 have the most severe type of the condition.
Before this approval, two other therapies were available for NPC, but neither had been shown to reduce the risk of death, and both carried age and weight restrictions that limited access for the youngest and most severely affected patients, the FDA noted.
Lembaz is administered by a trained healthcare provider as an injection directly into the spinal canal — a procedure called an intrathecal injection — every two weeks.
To assess whether Lembaz reduced the risk of death, the FDA reviewed the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program. All patients had neurological manifestations of NPC that occurred before age 6. The FDA noted that patients receiving Lembaz experienced a 55% lower risk of death and lived longer than those in a matched external control group, with a median survival of 8.5 years versus 4.9 years. This advantage persisted even when patients also used miglustat, an off-label NPC treatment..
The most common side effects of Lembaz include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. The medication's label includes a boxed warning about hearing damage, which can involve irreversible deafness. Patients must undergo a thorough hearing assessment prior to beginning Lembaz and at routine intervals during therapy, and the dosage may be modified depending on the findings from those check-ups, according to the FDA.
“For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” said Acting FDA Commissioner Kyle Diamantas, J.D., in the press release. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”
Lembaz received Breakthrough Therapy designation from the FDA. The agency granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.
For university students studying medicine, pharmacology, or genetics, this approval represents a significant real-world example of how translational research can move from understanding a rare disease mechanism to delivering a therapy that demonstrably extends life. It also highlights the importance of regulatory pathways like Breakthrough Therapy designation in accelerating access to treatments for conditions with high unmet medical need.